We would love to hear your thoughts about our site and services, please take our survey here.
Yes Moonparty - or a micro-bagger !
Hi Violin - some good answers to your 15.55 so I hope that puts your concerns about Redmile's holding finally to bed. I'd add MO that Scancell won't be going anywhere for 50p . . .
And thanks to Ray and Chester for an excellent and enlightening discussion about the magic 30. Any update we get on SCOPE progress will be exciting. Maybe an RNS and maybe not.
Tuesday 2pm tick tock.
Hi Violin. Re. your last sentence, I disagree 100%. IMHO that's just not how it works, whatever the figures. We'll see. Roll on Tuesday 2 pm. GN
Kashdog, I agree with you. Jambo should keep his chin up because the vagaries of the SP ups and downs have long defied all logic. I'd suggested that some 'experienced Investors' will have suffered too!
Kashdog - re. 2019 - nice timing. GLA
Hi Chester, with respect, 'to engage with investors or analysts', is IMO, always an excellent use of management time.
There MAY not be anything new to disclose. IF there is, it'll be the subject of an RNS IMO. The Interims is a statutory disclosure of accounting data for the 6 months to 31/10 to which is added a review of matters of any business progress since 31/10
We were the first to feel let down when the previous Investors/Analysts discussion was cancelled and it may be that Scancell, to their credit, are now putting that right - great - something is likely to be learnt from what is said and the way it is said.
OR, there may be something new, in an RNS, but hopes need not come crashing down again, if there is not. That's all.
There's much to come soon enough, be it Tuesday or not . . . ATB
Chester 14.34 - "I cannot see any logical reason to be giving a presentation on Tuesday that is just going over old ground". Well I can - it's communication and IR. If there's any 'new ground' there will be a separate RNS IMO. I suspect Scancell's logical reason for Tuesday 2 pm is to repair the loss of the previously promised Presentation/Q & A which when cancelled before in understandable circumstances, was the subject of universal disdain here.
Chester re. "who are they trying to engage", you seem to infer something or other. IMO it's just Scancell, trying to engage with Investors and Analysts who were disappointed before.
"It has to be an extra bit of something". Oh really? In truth, it has or has not to be.
Violin 09.28 - 'it's' never "done and dusted" - hang on - 'it' is ongoing until we get there. As to 'curve ball', "Nasdaq", I'm quite certain, that if ever that's envisaged that will be a long saga not related to 'Interims' stuff. And 12.51 - "I would have certainly changed auditors", I was waiting for that one. You know what I think.
The Interims are a 6 month update on the financial position of Scancell which includes an update of material events and business prospects - what used to be 'post-balance sheet events'.
If there is any new data or other excitement, we should be told that in an RNS which Interims or not, would be posted anyway.
Well done Scancell for setting up Tuesday's 2 pm event. rom the 'Interims' and the Q and A we should, quietly, be able to glean a little.
Unless, we get an RNS too !! GN
Hi C11 - re. notice - well they just squeezed it in ! 2 days !! But our wizards will have time to prepare some searching points for Q & A at the 'Investor Presentation'.
Should be an interesting day . . . . ATB
Kashdog, yes the triple lock and public service pensions etc. should be on that list too. Sorry for O/T. Some great ON/T posts today !
Cleaner, for a moment, I thought you were giving up being a BioTech investor and going to stand for Parliament - (myself I would love to vote Labour but won't because of concerns about woke, immigration and defence).
But getting to the point, 'Robin' is well informed. Let's hope he's influential too.
BTW, a Starmer nightmare is not yet, a certainty IMO. ATB
Thanks very much indeed Burble.
I noticed from Cleaner's link that 'Kite' / Gilead are one of many affected by that FDA notice and recalled that 2017 acquisition, $11.9 billion https://www.gilead.com/news-and-press/press-room/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion
A nice sum - reminds me of what values can be reached around here. I remember being astonished at the time.
(BTW Cleaner, I have edited over there to clarify).
Cleaner, to emphasise, no-one will be happy if ANY promising avenue against cancer falters, but, coupled with the (should stay 'unattributed') comments from a Moderna Exec, about Moderna being in trouble if Scancell are right. MMMmmmm One to ponder . . . GN
Good links Cleaner and thanks for the heads up. A new thread ! ATB
Burble ? But Ruck and Ray are not, either of them, a Dwarf - so I'm told.
Good try Ruck and nice to see your confusion after recent traumas, has gone.
Or has it ? ATB
I'm not sure about that C11 . . . . Oct 2021 https://www.lse.co.uk/rns/SCLP/notice-of-interim-results-uaayvfwz2joxnly.html
As we've had 'notice' the last 2 years, it's likely we'll get notice for Oct 2023 and on that subject, where the digger is it ? ATB
Balerno - advance notice of the Interims is usual so if there is notice this week the update will be next week or later. Re. the Investor briefing, as Violin suggests, I guess that has been overtaken by events, (for now).
Violin as always it's a wait for news ANY day . . . . . (and a tough wait for news everyday!).
So we have a 'pregnant silence' again, that being some 'calm before the storm', (which hopefully is about to transpire . . . . )
Very strange to see NO posts on a trading day.
A bit more data and the Interims report will be good to see.
(C7 good to see you punching as ever. ATB)
Nice one Cleaner and thanks to Burble too. If all goes well, Avidimab looks like a potential 'slam dunk' of the first order.
Perhaps with Patent lives in mind, 'time is of the essence'.
. . . or . . . https://uk.advfn.com/cmn/fbb/thread.php3?id=52251655
Yesterday 19/1 from the 'litter free' thread, over there, reply 33 onwards . . https://uk.advfn.com/cmn/fbb/thread.php3?
Supernumerary, Bermuda and Sci102 - (thanks to them). Bermuda concludes, "I'm assuming that even if they close the SCIB1 cohort to recruitment when they reach the required no. of responses, they'll still continue to dose, monitor and follow up all existing patients on that cohort in line with the trial protocol (dosing for 85 weeks and follow up for 2 years after first dose)so will still be gathering valuable data but in a few less patients and new patients can hopefully join the iSCIB1+ cohort."
I noted an earlier suggestion here, (by whom I don't remember), that recruitment to these trials could be completed before the end of Q2.